A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis

European Journal of Neurology

Volumn 19, Issue 2, 2012, Pages 307-311

  Fox, E J ^a   Sullivan, H C ^b   Gazda, S K ^c   Mayer, L ^a   O'Donnell, L ^b   Melia, K ^d   Lake, S L ^d  

^a Central Texas Neurology Consultants PA   (United States)

^b Saint Mary's Health Care   (United States)

^c Integra Clinical Research   (United States)

^d GENZYME CORPORATION   (United States)

Author keywords

Alemtuzumab; Beta interferon resistance; Clinical trials; Multiple sclerosis; Refractory

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG SCREENING; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; GRAVES DISEASE; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LUNG EMBOLISM; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTPATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; RASH; RECURRENCE RISK; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 84856057894     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03507.x     Document Type: Article

References (13)

1. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108.
2. Coles AJ and the CAMMS223 Study Group. Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis. N Engl J Med 2008; 359: 1786-1801.
3. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
4. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
5. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.
6. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691-1695.
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
8. The IFNB Multiple Sclerosis Study Group. Interferon beta-1a is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind placebo-controlled trial. Neurology 1993; 43, 655-661.
9. PRISMS. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352:1498-1504. [Erratum in Lancet 1999 Feb 20; 353(9153):678].
10. Limmroth V, Malessa R, Zettl U, et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol 2007; 254: 67-77.
11. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
12. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
13. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neurology 2002; 58: 1294-1296.